Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00719472 · FLOW

Participant flow

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) · Source last updated 2017-05-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
    id
    FG000
    title
    Rituximab 375 mg/m^2
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician decision to withdraw patient
    2. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Subject decision to withdraw
    3. reasons
      1. group Id
        FG000
        num Subjects
        17
      type
      Various Reasons
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        451
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        425
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      NOT COMPLETED
    title
    Enrolled in Study
  2. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        11
      type
      Eligibility criteria for Cycle 2 not met
    4. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Physician decision to withdraw patient
    5. reasons
      1. group Id
        FG000
        num Subjects
        9
      type
      Subject decision to withdraw
    6. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Various Reasons
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        425
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        372
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      NOT COMPLETED
    title
    Received Cycle 1 Treatment
  3. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        12
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Disease progression
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Lost to Follow-up
    5. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Physician decision to withdraw patient
    6. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Subject decision to withdraw
    7. reasons
      1. group Id
        FG000
        num Subjects
        25
      type
      Various Reasons
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        372
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        304
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        68
      type
      NOT COMPLETED
    title
    Received Cycle 2 Treatment
pre Assignment Details
Of 451 enrolled patients, 26 withdrew before receiving treatment and are not included in the Baseline Characteristics nor any of the Outcome Measures.
Complete source fields
groups
  1. description
    Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
    id
    FG000
    title
    Rituximab 375 mg/m^2
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician decision to withdraw patient
    2. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Subject decision to withdraw
    3. reasons
      1. group Id
        FG000
        num Subjects
        17
      type
      Various Reasons
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        451
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        425
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      NOT COMPLETED
    title
    Enrolled in Study
  2. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        11
      type
      Eligibility criteria for Cycle 2 not met
    4. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Physician decision to withdraw patient
    5. reasons
      1. group Id
        FG000
        num Subjects
        9
      type
      Subject decision to withdraw
    6. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Various Reasons
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        425
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        372
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        53
      type
      NOT COMPLETED
    title
    Received Cycle 1 Treatment
  3. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        12
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Disease progression
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Lost to Follow-up
    5. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Physician decision to withdraw patient
    6. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Subject decision to withdraw
    7. reasons
      1. group Id
        FG000
        num Subjects
        25
      type
      Various Reasons
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        372
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        304
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        68
      type
      NOT COMPLETED
    title
    Received Cycle 2 Treatment
pre Assignment Details
Of 451 enrolled patients, 26 withdrew before receiving treatment and are not included in the Baseline Characteristics nor any of the Outcome Measures.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice